Multiple Myeloma Market - PowerPoint PPT Presentation

About This Presentation

Title:

Multiple Myeloma Market

Description:

The Multiple Myeloma Market would experience the CAGR of 4.5% from 2021 to 2028. The major countries contributing to the growth of the market are the United States, Eu5 (the UK, Germany, France, Italy, Spain), China and Japan. Multiple myeloma (MM), is a rare type of cancer formed in the white blood cell also called as plasma cell. Normal plasma cells are an important part of immune system which are found in the bone marrow (soft tissue bones). The immune system is made of several types of cells which work together to fight infections and other diseases. Lymph cells are the main types of white blood cells in immune system and also includes T and B cells. These cells can be in any areas of the body like nymph nodes, bone marrow, intestines, and bloodstream. When B cells counter to an infection, they mature and changes to plasma cells. Plame cells produces antibodies, which can help the body attack and then kill germs. – PowerPoint PPT presentation

Number of Views:77

Slides: 9

Provided by: priyasharma1

Category:

more less

Transcript and Presenter's Notes

Title: Multiple Myeloma Market

1
Multiple Myeloma Market
sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
2
Multiple Myeloma Market Global Scenario, Market
Size, Outlook, Trend, and Forecast, 2019 2028

The Multiple Myeloma Market would experience the
CAGR of 4.5 from 2021 to 2028. The major
countries contributing to the growth of the
market are the United States, Eu5 (the UK,
Germany, France, Italy, Spain), China and Japan.
Multiple myeloma (MM), is a rare type of cancer
formed in the white blood cell also called as
plasma cell. Normal plasma cells are an important
part of immune system which are found in the bone
marrow (soft tissue bones). The immune system is
made of several types of cells which work
together to fight infections and other diseases.
Lymph cells are the main types of white blood
cells in immune system and also includes T and B
cells. These cells can be in any areas of the
body like nymph nodes, bone marrow, intestines,
and bloodstream. When B cells counter to an
infection, they mature and changes to plasma
cells. Plame cells produces antibodies, which can
help the body attack and then kill germs.
When plasma cells become uncontrollable and grow
out of control then it becomes cancerous, this is
termed as multiple myeloma. These plasma cells
make an abnormal protein or antibody which is
known by several names like monoclonal
immunoglobulin, monoclonal protein, M-spike.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
3
Market Dynamics

Increased prevalence of multiple myeloma market
augments the growth of the market as numerous
forms of blood cancer is increasing including the
multiple myeloma which is considered as rare type
which needs efficient and advanced therapeutics
resulting in positive clinical outcomes for
patients. There is increase in RD activity which
is efficient in boosting the multiple myeloma
market. Despite the increase of these cases
higher costs of treatment leads to limited market
growth also lack of awareness and appropriate
payment plans in the emerging countries hinders
the growth.
North America hold the substantial market share
at present. This is characterized by increased
prevalence and demand for the treatment coupled
with increase in the diagnosis of disease by
adopting advanced therapeutics. All these factors
along with high healthcare expenditure, patient
population for new treatments and presence of
upcoming launches are responsible for substantial
market share of the region. The total cases
reported in the year 2020 was 91,693 in the 8 MM
of which US accounted 32,270. In the case of EU-5
countries, Germany reported maximum cases of
Multiple Myeloma of 21,116 in 2020. The cases in
males are more likely to develop Multiple Myeloma
than females (about 55 percent of cases).

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
4
Multiple Myeloma Diagnosis requires

Plasma cell tumor.
Any one of the below.
High blood calcium cells
Poor kidney function
Low RBC
Holes in bones from tumor
Above 60 plasma cells in bone marrow
Multiple Myeloma Market is segmented based on
therapy and by drug type, distribution channel,
and region. Based on therapy, it categorized as
targeted therapy, biologic therapy, and
chemotherapy. On the basis of drug type, it is
categorized as Immunomodulatory Drugs, Proteasome
Inhibitors, Histone Deacetylase Inhibitors,
Monoclonal Antibody Drugs, and Steroids.

sales_at_accurizemarketresearch.com Copyright 2021
Accurize Market Research
5

Furthermore, based on distribution it is
categorized as Hospital Pharmacies, Retail
Pharmacies Drug Stores and Online Pharmacies.
Moreover, on the basis of geography it is
categorized as North America (US, Canada, Rest of
North America), Europe (UK, Germany, France,
Italy, Spain, Scandinavia, Rest of Europe), Asia
Pacific (India, China, Japan, Australia, Rest of
Asia Pacific), Rest of the World (Latin America
(Brazil, Mexico, Rest of Latin America), Middle
East Africa (South Africa, GCC, Rest of Middle
East Africa)).
Global market reflects an increasingly intense
competition scene with the presence of many
market leaders of oncology with them enlarge
portfolio of cancer treatment. Key major players
in the multiple myeloma market are Takeda
Pharmaceutical Company Limited, Celegene
Corporation, Kyprolis, Bristol Myers Squibb
Company, AbbVie Inc., Sanofi and others.